Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances

Eledon Pharmaceuticals, Inc.

2022-Q3 EPS reported -$2.07

Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.
Cash and equivalents $65.9M as of Sep 30, 2022; runway into 2024.
FDA cleared IND for Phase 2 trial of tegoprubart in kidney transplant prevention.
FDA cleared IND for tegoprubart in IgA Nephropathy; global Phase 2a enrolling.
Initial data from kidney, islet cell, and IgAN studies expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eledon Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $10.5 million, EPS $0.73 per share.

Period: the three months ended September 30, 2022
Net income: $10.5 million
EPS: $0.73 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $10.5 million, or $0.73 per share, for the three months ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.